Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Opinion & Analysis (NDAQ:VIRX)

    Sunesis Pharmaceuticals shifts focus to leukemia drug

    The Life Sciences Report May 18, 2017

    How three companies have been resurrected from failed clinical trials:George Zavoico of JonesTrading

    The Life Sciences Report April 6, 2016

    BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

    Gail Dutton October 1, 2015

    CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

    Gail Dutton September 10, 2015

    Novel technology platforms with dramatic growth potential: Wedbush's David Nierengarten

    George S. Mack August 26, 2015

    Capitalize on comeback stories in micro-cap biotech: Joe Pantginis of ROTH Capital Partners

    George S. Mack June 17, 2015